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Background: The most commonly used biomarkers to predict the response of breast cancer patients to therapy
are the oestrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2
(HER2). Patients positive for these biomarkers are eligible for specific therapies such as endocrine treatment in the
event of ER and PgR positivity, and the monoclonal antibody, trastuzumab, in the case of HER2-positive patients.
Patients who are negative for these three biomarkers, the so-called triple negatives, however, derive little benefit
from such therapies and are associated with a worse prognosis. Deregulation of the protein serine/threonine
phosphatase type 2A (PP2A) and its regulatory subunits is a common event in breast cancer, providing a possible
target for therapy.
Methods: The data portal, cBioPortal for Cancer Genomics was used to investigate the incidence of conditions that
are associated with low phosphatase activity. Four (4) adherent human breast cancer cell lines, MDA-MB-468,
MDA-MB-436, Hs578T and BT-20 were cultured to assess their viability when exposed to various dosages of
rapamycin or FTY720. In addition, RNA was extracted and cDNA was synthesised to amplify the coding sequence of
PPP2CA. Amplification was followed by high-resolution melting to identify variations.
Results and conclusion: The sequence of PPP2CA was found to be conserved across a diverse panel of solid
tumour and haematological cell lines, suggesting that low expression of PPP2CA and differential binding of
inhibitory PPP2CA regulators are the main mechanisms of PP2A deregulation. Interestingly, the cBioPortal for
Cancer Genomics shows that PP2A is deregulated in 59.6% of basal breast tumours. Viability assays performed to
determine the sensitivity of a panel of breast cancer cell lines to FTY720, a PP2A activator, indicated that cell lines
associated with ER loss are sensitive to lower doses of FTY720. The subset of patients with suppressed PP2A activity
is potentially eligible for treatment using therapies which target the PI3K/AKT/mTOR pathway, such as phosphatase
activators.
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Breast cancer accounts for approximately 23% of cancer
cases in females and is responsible for 14% of cancer-
related deaths in females [1]. The classification of breast
cancer is shifting to an expression-oriented classification.
Histological assessment is still a vital tool for assessing
prognosis through stage (lymph node status, tumour size* Correspondence: godfrey.grech@um.edu.mt
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article, unless otherwise stated.and grade). Immunohistological investigations are in-
strumental in defining subtypes and for planning treat-
ment strategies. Breast cancer is being classified into
four broad categories: luminal A, luminal B, the human
epidermal growth factor receptor 2 (HER2)-enriched
and basal-like. The luminal class indicates oestrogen re-
ceptor (ER) and/or progesterone receptor (PgR) positiv-
ity but a negative HER2 and a low Ki-67 expression
(<14%) for the A subtype. Luminal B is subdivided
into the HER2 negative along with high Ki-67 and
the HER2 positive. The HER2-enriched are negativentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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in its majority negative for all threehormone receptors
(triple negative). ER and PgR receptor expression con-
fers susceptibility to endocrine therapy whereas
HER2-positive breast cancer is treated with trastuzu-
mab (anti-HER2 treatment) [2,3].
Treatment of the basal-like class is currently based on
cytotoxic drugs and have a worse overall and disease-
free survival [2,4]. A small subclass, referred to as the
special histological types (being medullary and adenoid
cystic carcinomas) can still be eligible to endocrine treat-
ment [2]. Interestingly, the basal subtype shows a higher
occurrence of phosphatidylinositol 3-kinase (PI3K) path-
way activation [5].
Receptor tyrosine kinases such as HER2 and insulin-
like growth factor 1 (IGF-1) receptor activate the PI3K
pathway, initiating a cascade of signals. Active PI3K gen-
erates phosphatidylinositol 3,4,5 triphosphate (PIP3),
which serves as an anchor for Pleckstrin homology (PH)
domain-containing proteins, including both adaptor
molecules such as GRB2-associated binding protein 2
(Gab2) and docking protein 1 (Dok1) and kinases such
as tec protein tyrosine kinase (Tec), Bruton agamma-
globulinemia tyrosine kinase (Btk), phosphoinositide-
dependent kinase-1 (PDK1) and v-akt murine thymoma
viral oncogene homolog kinase (AKT) [6-9]. Activation
of AKT increases cell cycle progression and maintains
mammalian target of rapamycin (mTOR) signalling result-
ing in enhanced cell proliferation and survival, respect-
ively. The PI3K pathway is attenuated by phosphatases,
including phosphatase and tensin homolog (PTEN) which
dephosphorylates PIP3 [10] and protein serine/threonine
phosphatase type 2A (PP2A) which inactivates mTOR
effectors [11].
PP2A is a complex of multiple subunits that interact
to define the enzyme’s substrate targets. Moreover, other
regulatory subunits may bind to the complex to regulate
its activity. Hence, understanding the structure of PP2A
and its interactions with associated proteins sheds light
on its regulation and its substrates. PP2A controls the
phosphorylation of a number of kinases involved in cell
signalling by catalysing dephosphorylation of the down-
stream intracellular proteins. As PP2A activity regulates
various pathways, its downregulation may be involved in
the progression of multiple tumour types [12,13]. The
role of PP2A has been studied extensively in various cel-
lular models, and deregulation of PP2A and its subunits
(alpha4 and SET) are implicated in enhanced prolifera-
tion and differentiation block in haematopoietic progenitor
cultures [14]. Missense mutations in the structural subunits,
PPP2R1A and PPP2R1B, result in suppressed PP2A com-
plex formation. Loss of heterozygosity is observed in a sig-
nificant percentage of breast, lung, ovarian, colon and
liver and melanoma malignancies and to a lesser extent innon-Hodgkin’s lymphomas and chronic lymphocytic leu-
kaemia [15-20]. Somatic missense mutations were also de-
tected in PPP2R1A in high-grade serous endometrial
tumours [21]. A particular study has shown that PPP2R1B
is mutated in 13% of breast cancers, and these mutations
result in defective attachment of the B and C subunits.
Whole gene deletions, missense, frame-shift, internal and
C-terminal protein deletions are likely to hinder the for-
mation of the PP2A active core dimer. Half of the breast
cancers investigated had a low expression of PPP2R1B, con-
tributing to malignant transformation [17,22]. In fact,
PPP2R1B has been described as a tumour suppressor
gene as it is often found to be deleted in human breast
cancer. In addition, inactivation of PP2A by phosphor-
ylation at tyrosine 307 is significantly correlated with
HER2-positive tumour progression [23].
Loss of function of the phosphatases PTEN [24] and
inositol polyphosphate 4-phosphatase type II (INPP4B)
[25] is associated with aggressive basal-like breast carcin-
oma. PTEN, INPP4B and PP2A are known antagonists of
AKT phosphorylation; hence, loss of phosphatase function
leads to increased AKT activation. Interestingly, BRCA1 is
known to activate PP2A, a phosphatase that dephosphory-
lates AKT at threonine 308 (T308) and serine 473 (S473)
[26,27]. This is supported by the findings that loss of
BRCA1 activity leads to increased AKT activity [28] and
reduced PP2A activity [26]. In addition, BRCA1 is known
to bind phosphorylated AKT (p-AKT) and lead to its ubi-
quitination [29]. In fact, an enhanced stability and higher
expression of p-AKT can be found in BRCA1 mutants, in
which the mutant BRCA1 lacks the ability to bind to p-
AKT [28].
Overexpression of the PP2A biomarkers p-S6K and p-
AKT has been described in breast and ovarian tumours
potentially reflecting attenuated PP2A activity [30-33].
New insights into the mechanism of PP2A regulation in
solid tumours form the basis of potential identification
of variants that affect the phosphatase activity. The regu-
lating subunits CIP2A (cancerous inhibitor of PP2A, also
known as KIAA1524) and SET bind to the PP2A com-
plex and specify its targets. These subunits were found
to be overexpressed in various tumours including breast,
colon and renal tumours, respectively [34-36].
In this study, we scanned for mutations in the PP2A
catalytic subunit, PPP2CA transcript (mRNA) in various
breast cancer cell lines. Publically available datasets
(cBioPortal) were used to investigate the frequency of
mutations and expression of the PP2A complex compo-
nents and regulatory subunits. Of interest, the cBioPor-
tal for Cancer Genomics shows that the PP2A complex
is deregulated in 59.6% of basal breast tumours. Investi-
gations to determine the sensitivity of a panel of breast
cancer cell lines to FTY720, a PP2A activator, indicated
that cell lines associated with ER loss are sensitive to
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inhibitor of the mTOR kinase, rapamycin, on the same
panel of breast cancer cell lines resulted in a different
sensitivity profile. Our interest in the use of FTY720
originates from the observations in our preliminary
studies showing enhanced sensitivity of a BRCA1 mutant
breast cancer cell line to FTY720 (unpublished).
These cases are eligible to pharmaceutical inhibition of
the PI3K pathway and potentially activation of the phos-
phatase PP2A. Activation of PP2A will allow not only
targeting of the deregulated PI3K pathway, including
kinase mutants and cells with a low PTEN expression,
but also BRCA1 mutants due to the sensitivity conferred
by the lower PP2A activity.
Methods
Data mining using cBioPortal for Cancer Genomics
A data portal (cBioPortal for Cancer Genomics [37]),
available at http://www.cbioportal.org was used to meas-
ure the incidence of conditions that are associated with
low phosphatase activity, as per the criteria in Table 1
[37]. The database query was based on deregulation
(mutant and altered expression) of the PP2A complex
components and upregulation (expression) of the inhibi-
tory regulators of the complex.
Cell lines used and culturing conditions
Four (4) adherent human breast cancer cell lines were
used in the study, namely MDA-MB-468, MDA-MB-436,
Hs578T and BT-20. The cells were cultured in sterile T-25
flasks in an incubator at 37°C, having an atmosphere of
5% CO2 and 98% humidity, using RPMI 1640 medium
containing 10% foetal bovine serum (FBS) and 1% penicil-
lin/streptomycin. Passaging was carried out when the cells
reached around 90% confluence.
RNA extraction and cDNA synthesis
Cell pellets were prepared from 3 to 5 × 106 cells. Cells
were lysed in QIAzol and stored at −80°C. RNA was ex-
tracted using RNeasy isolation kit (Qiagen, Venlo, TheTable 1 Criteria used to select breast cancer cases with dereg
Variable
Selects low expression (including deletions) of one of the pp2a complex com
PPP2CA
PPP2CB
PPP2R2A
Selects high expression, including amplification, of the inhibitory regulatory s
KIAA1524 (cip2a)
SETBP1
SET
IGBP1 (alpha4)Netherlands). Quality was validated by spectrophotometry
260/280 and 260/230 ratios using the nanodrop, and the
integrity was checked using the Agilent Bioanalyser, Santa
Clara, CA, USA.
RNA was reverse transcribed into cDNA using the
Quantitect Reverse Transcription Kit from Qiagen. This
kit provides high cDNA yields even from low abundance
transcripts and eliminates genomic DNA contamination
effectively.
High-resolution melting
Primers were designed to amplify the coding sequence
of PPP2CA into individual 250 to 300 bp overlapping
fragments by polymerase chain reaction (PCR). Ampli-
fication was followed by HRM, using a Qiagen Rotor-
Gene instrument. Variants were characterised by their
melting temperatures through the distinct kinetics of
fluorescence loss during HRM. Shifts in the melting
temperature or HRM peaks were identified visually
using the Rotor-Gene software and also using the
Rotor-Gene ScreenClust HRM Software. The latter
software processes data generated throughout the amp-
lification and HRM in order to segregate samples into po-
tentially distinct groups. To characterise the variations,
the whole PPP2CA coding sequence was amplified using
the terminal primers in a conventional PCR. Products
were purified using the Wizard® SV Gel and PCR Clean-
Up System (Promega, Madison, WI, USA). The full-length
PPP2CA amplicons were sequenced to confirm the HRM
results.
Cell line sensitivity assays
The adherent human breast cancer cell lines described
above were plated in 24 well plates to determine two
seeding densities to be used for the sensitivity assays that
run for 48 h. Selection of the cell densities was based on
(1) reaching a confluence of 80% at the time point of
drug administration and in different wells (2) reaching a
confluence of 80% following 72 h of seeding. Cells were
plate in triplicates and incubated for 24 h to allowulated PP2A in the cBioPortal for Cancer Genomics
Criteria
ponents
Homozygous deletions; downregulation (fold change < −2)
ubunits
Amplification; upregulation (fold change >2)
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centration ranging from 0.5 to 25 μM, while rapamycin
was added in a separate experiment at a final concentra-
tion ranging from 10 to 100 μM. A vehicle control and an
untreated control were added. An MTT (3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was
performed at the end of the incubation periods (24 and
48 h) to determine cell viability. A replicate experiment to
confirm the results was done.
Results
In this study, no mutations were identified in the
PPP2CA coding sequence in various breast cancer cell
lines. In silico analysis using a publically available data-
set, the cBioPortal for Cancer Genomics, shows that the
protein phosphatase 2 (PP2A) complex is deregulated in
59.6% of basal breast tumours. In a panel of breast can-
cer cell lines, ER loss correlates with sensitivity to lower
doses of FTY720.
PPP2CA coding sequence is highly conserved
Screening of PPP2CA coding sequence for mutations,
using HRM analysis, could not detect mutations in the
adherent human breast cancer cell lines and in an add-
itional panel of 25 tumour cell lines (14 haematological
and 11 solid tumour cell lines). The wild-type sequence
was confirmed in the human breast cancer cell lines
used in this study (data not shown) by re-sequencing.
Protein phosphatase type 2A (PP2A) is deregulated in
59.6% of basal breast tumours
Analysing the results from datasets originating from
RNAseq in the cBioPortal, and using the criteria
described above, 46.7% (245 cases out of 525 eligible
cases) of all the subtypes of breast cancer patients either
had a low expression, including deletions, of one of the
PP2A complex components or a high expression, includ-
ing amplification, of the inhibitory regulatory subunitsFigure 1 Distribution of aberrations associated with low PP2A activity
Blue bars indicate low expression (light) or homozygous deletion (dark), wh
(KIAA1524 is equivalent to CIP2A; IGBP1 is equivalent to alpha4).(Figure 1). Interestingly, the criteria were generally mu-
tually exclusive, except for PPP2CB and the PPP2R2A
which can occur simultaneously.
Surprisingly, 8.6% of the patients either had a high ex-
pression of CIP2A (KIAA1524) or a high expression of
SET, implying that the PP2A complex is sequestered
from the negative feedback on mTOR signalling. Al-
though overall, the PPP2CA expression is low in 4.2% of
the patients, the low expression was associated mainly
with the basal phenotype. In addition, PP2A deregula-
tion is associated with 59.6% of the basal phenotype
(Table 2).
Cell lines associated with ER loss are sensitive to lower
doses of FTY720
The cell lines, BT20 and Hs578T, were found to be sen-
sitive to 0.05 and 0.1 μM FTY720, respectively. A signifi-
cant reduction in the metabolism of these cells persisted
up to 5 μM, with a percentage viability of 60% in BT20
and 80% in Hs578T, when compared to the vehicle con-
trol culture (Figure 2A). Of interest, both these cell lines
have no ER expression or express a truncated, inactive
ER. In contrast, the BT20 cell line is resistant to rapamy-
cin, while Hs578T was extremely sensitive to low doses
with an IC50 reached at 10 μM (Figure 2B). The other
breast cancer cell lines studied proliferated in the pres-
ence of 5 μM FTY720 and reached an IC50 at approxi-
mately 35 μM of rapamycin.
Results interpretation
In this study, we observed that the PPP2CA coding se-
quence is not polymorphic in various tumour cell lines
tested. The PPP2CA gene sequence is highly conserved
throughout species (ENSEMBLE version release 72 [38]).
Currently, 25 missense variants, 4 stop codon gains and
2 frame-shift variants have been described in literature.
Although the mutational analysis did not yield any mis-
sense mutations, in silico analysis of publically available. In this analysis, all subtypes of breast cancer patients were included.
ile the red bars indicate high expression (light) or amplification (dark)
Table 2 Incidence distribution of aberrations associated with low PP2A activity in the various breast cancer subtypes
Basal (N = 99) Luminal A (N = 235) Luminal B (N = 133) HER2-enriched (N = 58) Total (N = 525)
PPP2CA 17.2% 0.4% 2.3% 1.7% 4.2%
PPP2CB 21.2% 14.9% 30.8% 25.9% 21.3%
PPP2R2A 18.2% 11.9% 24.1% 24.1% 17.5%
CIP2A 18.2% 3.0% 10.5% 10.3% 8.6%
SETBP1 4.0% 6.4% 7.5% 0.0% 5.5%
SET 15.2% 2.6% 8.3% 24.1% 8.8%
IGBP1 4.0% 7.7% 2.3% 3.4% 5.0%
Total PP2A deregulation 59.6% 35.3% 51.9% 58.6% 46.7%
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regulation of the PP2A complex mainly occurs through
altered expression of the subunits and inhibitory regula-
tors. Indeed, 17.2% of cases with the basal subtype
showed low expression or homozygous deletion of the
catalytic subunit, PPP2CA; 18.2% were associated with
high expression of CIP2A and 15.2% with high expres-
sion of SET (Table 2). Overall, PP2A is deregulated in
59.6% of basal breast tumours.
Cytoplasmic CIP2A overexpression at mRNA and pro-
tein levels correlates with high tumour grade and aggres-
siveness in breast cancer patients [34,39]. Overexpression
of CIP2A in normal tissues is only restricted to brain,
prostate and testis, but it is undetectable in normal breast
tissue. Overexpression is a common occurrence in malig-
nancy including colon, prostate, ovarian cancer and head
and neck squamous cell carcinomas and is most often re-
lated to the more aggressive cases of high-grade or ad-
vanced tumour stages [35,40-43]. CIP2A overexpression
clustered mainly with basal-like breast tumours. Out of 40
breast cancer cell lines, basal-like breast tumour cell lines
exhibited the highest CIP2A overexpression [44]. Simi-
larly, SET and alpha4 (IGBP1) are implicated in promoting
the progression of disease and enhanced proliferative sig-
nals in leukaemogenesis [14,45]. Of interest, expression of
the alpha4 inhibitory subunit is dependent on the effi-
ciency of translation initiation, promoted by the mTOR
pathway. Hence, expression should be measured at a pro-
tein level, and the incidence of high alpha4 expression is
expected to be greater than 3% (Figure 1, IGBP1).
Although no data on the protein expression of alpha4 is
available in the cBioPortal, the Human Protein Atlas hints
to an increased expression of alpha4 protein in breast
tumour as opposed to normal breast tissue through im-
munohistochemical analysis.
Binding of alpha4 to the PP2A complex shifts the
phosphatase activity from a negative feedback mechan-
ism that attenuates proliferation (mTOR signalling) to a
pro-survival activity (Figure 3) through inactivation of
p53 [46-48]. To support the importance of substrate spe-
cificity following regulatory subunit binding to the PP2Acomplex, studies indicate that the SET-PP2A complex
activates the ERK/MAPK pathway inhibiting apoptosis
[49] and the CIP2A-PP2A complex releases inhibition
on p-AKT and c-Myc and hence promotes pro-
proliferative signals [50]. This implies that the PP2A
complex shifts from a tumour suppressor to a promoter
of oncogenic signals.
Deregulation of p53 is a frequent event in breast can-
cer associated with 33% of breast cancer patients [37].
Formation of the PP2A-alpha4 complex is an alternative
mechanism promoting cell survival through p53 inacti-
vation (Figure 3).
Another hallmark of the molecular basis of breast can-
cer is the loss of function of BRCA1. BRCA1 mutations
occur in approximately 50% of hereditary breast cancers,
but a low expression of this gene was observed in 40%
to 80% of cases [51]. Interestingly, BRCA1 has been
shown to activate PP2A [26], and a low BRCA1 expres-
sion correlate with elevated phosphorylation of AKT
[51]. In addition, IGF-1-induced activation of p-AKT is
inhibited by FTY720 in the BRCA1 mutant cell line,
HCC1937 (data not shown), indicating that loss of func-
tion of BRCA1 leads to low phosphatase activity and
higher sensitivity to PP2A activators.
In this study, viability assays showed that cell lines as-
sociated with oestrogen receptor (ER) loss are sensitive
to lower doses of FTY720. ER-negative breast cancer cell
lines have a suppressed PP2A activity, when compared
to breast cancer cell lines expressing ER receptors [52],
supporting the higher sensitivity to the phosphatase acti-
vator, FTY720. ER-dependent BRCA1 expression [53]
provides a plausible mechanism (Figure 3), since low ex-
pression of BRCA1 in ER-negative cell lines results in a
reduced ability to activate PP2A. Of interest, viability of
the ER-negative cell line, BT-20, was unaffected by rapa-
mycin up to a high dose (35 μM). Hence, the sensitivity
to PP2A activation in the BT-20 cell line is not
dependent on the attenuation of the mTOR kinase,
which is specifically inhibited by rapamycin. This sug-
gests that the formation of the core PP2A complex,
following pharmacological activation by FTY720,
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Figure 2 Viability assays of breast cancer cell lines. Cells were cultured in the presence or absence of FTY720 (A) or rapamycin (B) using a
concentration gradient and absorbance was measured after 48h of drug exposure. Each data point is an average of three independent
experiments, with triple measurements for each experiment. The viability of each well is expressed as a percentage normalised to vehicle control
cells. The standard error is indicated using error bars. The blue lines plot the percent viability of MDAMB468, the red line Hs578T, the green line
BT20 and the purple line of MDAMB436.
Baldacchino et al. The EPMA Journal 2014, 5:3 Page 6 of 9
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and S6K, and concurrently releases the block on the p53
pathway. Our results suggest that markers can be used to
predict sensitivity to FTY720 and that the pharmacological
activation of PP2A is an attractive therapeutic modality
that simultaneously targets proliferative signals and re-
leases PP2A-dependent p53 inhibition. In addition, the use
of FTY720 is a potential alternative therapy to inhibitors ofthe kinase mTOR, which proved to have limited success
due to resistance to therapy. A panel of biomarkers that
predict sensitivity to mTOR inhibitors [54] and activation
of the phosphatase, PP2A, merit further investigation to
allow characterisation of the potential therapeutic group.
This approach utilise the use of efficacy biomarkers, asses-
sing the beneficial effects of a clinically available treatment,
promoting personalised medicine [55].
Oestrogen
BRCA1
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ER loss
BRCA1 
mutation
Deregulation
Akt
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Alpha4
Dephosphorylation
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Complex
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PP2A 
Complex
Akt
P
P
Cytoplasmic membrane
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Figure 3 Schematic diagram illustrating the dual role of PP2A complex. PP2A complex attenuates the proliferative signals transduced via
the AKT/mTOR pathway. Activation of PP2A is dependent on ER-induced BRCA1 expression. Attenuation mechanism following
(A) haploinsufficiency or loss of function of ER or BRCA1 or (B) increased expression of the inhibitory regulatory subunit, alpha4. Alpha4
sequestrated the PP2A complex, maintaining AKT/mTOR signals and shifts the specificity of the PP2A-alpha4 complex towards pro-survival signals,
via dephosphorylation of p53.
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The characterisation of the molecular mechanism of dis-
ease allows classification of patients into subtypes and
potentially identifies specific targets for therapeutic
intervention. Tyrosine kinase mutations are central to
specific targeted therapy. Investigation of kinase deregu-
lation within particular patient groups has led toidentification of mutant tyrosine kinases associated with
disease progression and therapy modulation. Biomarker-
specific therapies emerged, taking a leading role in
guidedtherapy. Loss of function mutations in the phos-
phatase, PP2A, and/or an enhanced PP2A inhibition due
to increased expression of PP2A regulators (such as
CIP2A, SETBP1) will provide a new classification of
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will provide the basis to investigate the use of PP2A activa-
tors as therapeutic drugs, hence promoting personalised
medicine. Current diagnostic panels assessing risk, early
diagnosis and patient management require a more robust
platform, integrating classifier biomarkers, clinical data and
creation of individual patient profiles [56]. In this study, we
promote the use of biomarkers to assess the potential use
of specific drugs in stratified therapeutic groups.
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